`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MYLAN PHARMACEUTICALS INC.
`
`Petitioner
`
`v.
`
`YEDA RESEARCH AND DEVELOPMENT CO. LTD.
`
`Patent Owner
`
`Case No. IPR2015-00644
`
`Patent No. 8,399,413
`
`PATENT OWNER’S MOTION TO SEAL
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. §§ 42.14, 42.54, Patent Owner Yeda Research and
`
`Development Co. Ltd. (“Yeda” or “Patent Owner”) respectfully moves to seal
`
`portions of Exhibits 2108-2114, 2120-2122 and the Declaration of Henry
`
`Grabowski, Ph.D., Exhibit 2133 (“Grabowski Declaration”), filed herewith, which
`
`contain trade secrets and confidential business information of a third party, IMS
`
`Health Inc. (“IMS Health”). In support of this Motion, Yeda is also submitting an
`
`unopposed motion for entry of the Board’s default protective order (“Proposed
`
`Protective Order”). See 37 C.F.R. § 42.54(a).
`
`I.
`
`GOOD CAUSE EXISTS FOR SEALING CERTAIN CONFIDENTIAL
`INFORMATION
`
`In determining whether to grant a Motion to Seal, the Board must find “good
`
`cause” and “strike a balance between the public's interest in maintaining a
`
`complete and understandable file history and the parties’ interest in protecting truly
`
`sensitive information.” 37 C.F.R. § 42.54(a); 77 Fed. Reg. 48756, 48760 (Aug. 14,
`
`2012). As described in the Office Trial Practice Guide, the Board identifies
`
`confidential information in a manner “consistent with Federal Rule of Civil
`
`Procedure 26(c)(1)(G), which provides for protective orders for trade secret or
`
`other confidential research, development, or commercial information.” 77 Fed.
`
`Reg. 48756, 48760 (Aug. 14, 2012).
`
`
`
`1
`
`
`
`Exhibits 2108-2114, 2120-2122 and the Grabowski Declaration disclose
`
`proprietary data provided by third party IMS Health concerning sales,
`
`prescriptions, and promotional spending concerning Copaxone® 40 mg/mL and its
`
`competitors (“IMS data”). Exhibits 2108-2114 and 2120-2122 contain summaries
`
`and graphs of IMS data and Dr. Grabowski’s calculations based on IMS data. The
`
`Grabowski Declaration discloses the IMS data and related calculations contained
`
`in Exhibits 2108-2114 and 2120-2122. Patent Owner obtained access to IMS data
`
`pursuant to a license agreement that obligates Patent Owner to maintain the data as
`
`confidential. (IMS Health represents that IMS data retains its value to IMS only
`
`when access to the data is restricted. IMS also represents that it owes contractual
`
`duties of confidentiality to its sources.)
`
`The public’s interest in accessing this information for the purposes of the
`
`patentability of the challenged claims in this proceeding is outweighed by the
`
`prejudicial effect that such disclosure would have on IMS. The IMS data is being
`
`provided in support of the Grabowski Declaration. In conjunction with this
`
`motion, Yeda is submitting non-confidential, redacted versions of the Grabowski
`
`Declaration and Exhibits 2108-2114 and 2120-2122. The substance of Dr.
`
`Grabowski’s opinions can be fully ascertained from the redacted declaration and
`
`exhibits; the only information not reflected in the redacted declaration and exhibits
`
`is IMS data and Dr. Grabowski’s specific calculations based on that data.
`
`
`
`
`2
`
`
`
`Moreover, interested members of the public can obtain the data in question directly
`
`from IMS Health (with any appropriate fee). In contrast, the public disclosure of
`
`IMS data would deprive IMS Health of the value of its proprietary information.
`
`The Board has previously allowed the sealing of similar information. See, e.g., St.
`
`Jude Med., Cardiology Div., Inc. v. Bd. of Reg. of Univ. of Michigan, IPR2013-
`
`00041, Paper 32 (P.T.A.B. Nov. 16, 2013) (granting motion to seal tables
`
`containing IMS data). Accordingly, good cause exists to seal the IMS data
`
`contained in Exhibits 2108-2114, 2120-2122 and the Grabowski Declaration.
`
`For the foregoing reasons, the Board should seal the unredacted versions of
`
`Exhibits 2108-2114, 2120-2122 and the Grabowski Declaration.
`
`II.
`
`CERTIFICATION OF NON-PUBLICATION
`
`To the undersigned counsel’s knowledge, the information sought to be
`
`sealed by this motion has not been published or otherwise made public.
`
`III. CERTIFICATION OF CONFERENCE WITH OPPOSING PARTY
`PURSUANT TO 37 C.F.R. § 42.54.
`
`Patent Owner has conferred with Petitioner, and Petitioner does not oppose
`
`the entry of the default protective order in this proceeding and the motion seal.
`
`THEREFORE, Patent Owner respectfully requests that the Board grant
`
`Patent Owner’s Motion to Seal.
`
`
`
`
`3
`
`
`
`Respectfully submitted,
`
`/Elizabeth J. Holland/
`
`Elizabeth J. Holland
`Registration No. 47,657
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10019-1405
`Tel: 212-813-8800
`Fax: 212-355-3333
`
`Dated: November 20, 2015
`
`
`
`
`4
`
`
`
`CERTIFICATION OF SERVICE
`
`The undersigned hereby certifies that the foregoing PATENT OWNER’S
`
`MOTION TO SEAL was served electronically via e-mail on November 20, 2015
`
`on the following:
`
`Jeffrey W. Guise
`
`jguise@wsgr.com
`
`Brandon M. White
`
`BMWhite@perkinscoie.com
`
`Shannon Bloodworth
`
`sbloodworth@perkinscoie.com
`
`David Anstaett
`
`DAnstaett@perkinscoie.com
`
`Richard Torczon
`
`rtorczon@wsgr.com
`
`
`
`/Elizabeth Holland/
`Counsel for Patent Owner
`
`
`
`Dated:
`
`November 20, 2015